Literature DB >> 27071048

Diagnosis and Management of Congenital and Acquired FXIII Deficiencies.

László Muszbek1, Éva Katona1.   

Abstract

Inherited deficiency of FXIII A subunit (FXIII-A) is a rare (1:2,000,000) but very severe bleeding diathesis. The incidence is much higher in communities where the practice of consanguineous marriage is combined with founder effect mutation. Because of the high risk of intracranial bleeding, life-long prophylaxis, preferably using FXIII concentrate, is mandatory. In FXIII-B subunit deficiency the bleeding diathesis is mild to moderate. FXIII deficiency is frequently associated with impaired wound healing. Women suffering from FXIII deficiency cannot carry pregnancies to term; in severe cases spontaneous abortion occurs in the first trimester. Plasma-derived heat-inactivated FXIII concentrate and recombinant FXIII-A are available for prophylaxis; a 4 weekly dose of 35 to 40 U/kg is recommended and a trough level of greater than 5% FXIII activity should be aimed for. During pregnancy, 2 weekly prophylaxis with a target trough level of greater than 10% is recommended, and during labor FXIII activity should exceed 30%. During surgical procedures, the target should be higher than 50% FXIII activity. Alloantibodies make FXIII deficiency difficult to manage, but fortunately they are extremely rare. Acquired FXIII deficiency may involve both subunits. Autoantibodies against FXIII subunits also manifest in severe bleeding complication with a relatively high mortality rate. The first-line test in the diagnosis of FXIII deficiency should be a quantitative functional assay based on the measurement of ammonia release or amine incorporation. The sensitivity of the traditional clot solubility assay is not sufficiently robust to enable proper screening. Antigen assays are needed for the classification of FXIII deficiencies. In the case of anti-FXIII antibodies, the diagnostic armory should be supplemented by a mixing test/Bethesda-type inhibitor assay and by assays that detect/measure the binding of antibodies to FXIII and to its subunits. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27071048     DOI: 10.1055/s-0036-1572326

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  20 in total

1.  Impaired factor XIII activation in patients with congenital afibrinogenemia.

Authors:  Françoise Bridey; Claude Négrier; Cedric Duval; Robert Ariëns; Philippe de Moerloose; Alessandro Casini
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

Review 2.  What Is the Biological and Clinical Relevance of Fibrin?

Authors:  Rustem I Litvinov; John W Weisel
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

3.  Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients.

Authors:  Marina Marchetti; Patricia Gomez-Rosas; Laura Russo; Sara Gamba; Eleonora Sanga; Cristina Verzeroli; Chiara Ambaglio; Francesca Schieppati; Francesco Restuccia; Ezio Bonanomi; Marco Rizzi; Stefano Fagiuoli; Andrea D'Alessio; Grigorios T Gerotziafas; Luca Lorini; Anna Falanga
Journal:  Front Cardiovasc Med       Date:  2022-06-10

4.  Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors.

Authors:  Joan D Beckman; Raj S Kasthuri; Alisa S Wolberg; Alice D Ma
Journal:  Haemophilia       Date:  2018-08-24       Impact factor: 4.287

5.  Acquired Factor XIII Deficiency Inducing Recurrent and Fatal Bleeding, Description of a Case.

Authors:  Pierpaolo Di Micco; Gualberto Gussoni; Filippo Pieralli; Mauro Campanini; Francesco Dentali; Andrea Fontanella
Journal:  J Blood Med       Date:  2020-01-30

6.  The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations.

Authors:  Sravya Kattula; Zsuzsa Bagoly; Noémi Klára Tóth; László Muszbek; Alisa S Wolberg
Journal:  J Thromb Haemost       Date:  2020-02-28       Impact factor: 5.824

Review 7.  Advances of Coagulation Factor XIII.

Authors:  Da-Yu Shi; Shu-Jie Wang
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

8.  Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.

Authors:  Arshi Naz; Muhammad Younus Jamal; Samina Amanat; Ikram Din Ujjan; Akber Najmuddin; Humayun Patel; Fazle Raziq; Nisar Ahmed; Ayisha Imran; Tahir Sultan Shamsi
Journal:  Orphanet J Rare Dis       Date:  2017-04-07       Impact factor: 4.123

9.  Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.

Authors:  Manuel Carcao; Carmen Altisent; Giancarlo Castaman; Katsuyuki Fukutake; Bryce A Kerlin; Craig Kessler; Riitta Lassila; Diane Nugent; Johannes Oldenburg; May-Lill Garly; Anders Rosholm; Aida Inbal
Journal:  Thromb Haemost       Date:  2018-02-15       Impact factor: 5.249

10.  Mild Acquired Factor XIII Deficiency and Clinical Relevance at the ICU-A Retrospective Analysis.

Authors:  Felix Carl Fabian Schmitt; Maik von der Forst; Wolfgang Miesbach; Sebastian Casu; Markus Alexander Weigand; Sonja Alesci
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.